Results 21 to 30 of about 73,504 (266)
Population-based estimates of the effectiveness of pneumococcal vaccination in Australia
International Journal of Population Data Science, 2017 Objectives Australia’s Childhood Immunisation Register (ACIR) is one of only a handful of national immunisation registers world-wide. We have, for the first time, linked the ACIR to other health datasets to measure the real-world impact of Australia’s ...
Heather Gidding +6 more
doaj +1 more source
Microbiology Spectrum, 2014 ABSTRACTStreptococcus pneumoniaeis a Gram-Positive pathogen that is a major causative agent of pneumonia, otitis media, sepsis and meningitis across the world. The World Health Organization estimates that globally over 500,000 children are killed each year by this pathogen. Vaccines offer the best protection againstS. pneumoniaeinfections.
D. E. Briles +4 more
openaire +4 more sources
Brazilian Journal of Infectious Diseases, 2016 Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two ...
Carolina Regis Leite +5 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2017 Invasive pneumococcal infections among children are a serious public health problem in many countries, including Turkey. Pneumococcal conjugate vaccine has been included in Turkey's National Immunization Programme since 2009.
Ayşe Büyükcam +6 more
doaj +1 more source
Recent progress in pneumococcal protein vaccines
Frontiers in Immunology, 2023 Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence ...
Sha Li +4 more
doaj +1 more source
An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. [PDF]
, 2005 BACKGROUND: Polysaccharide pneumococcal vaccination for older adults is being introduced in developed country settings. Evidence of protection by this vaccine against pneumococcal pneumonia, or confirmation that illness and death from bacteraemia are ...
Cutts, Felicity T +3 more
core +1 more source
Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. [PDF]
, 2008 BACKGROUND: The study describes the molecular epidemiology of Streptococcus pneumoniae causing invasive disease in Gambian children METHODS: One hundred and thirty-two S. pneumoniae isolates were recovered from children aged 2-29 months during the course
Adegbola, Richard A +14 more
core +2 more sources
Expert Review of Vaccines, 2018 Introduction: Pneumococcal diseases (including septicemia, meningitis, pneumonia, and upper respiratory infections) constitute a major public health problem.
Tomas Mrkvan +4 more
doaj +1 more source
Indian Journal of Medical Microbiology, 2018 Streptococcus pneumoniae continues to take a heavy toll on childhood mortality and morbidity across the developing world. An estimated 10.6 million invasive pneumococcal diseases (IPDs) occur every year, with nearly 1 million deaths in children under 5 years of age. Introduction of vaccines in the childhood immunisation programme in developed world has
Anand, Manoharan, Ranjith, Jayaraman
openaire +2 more sources
Changes in the Features of Invasive Pneumococcal Disease after Introduction of the Seven-valent Pneumococcal Conjugate Vaccine in a Regional Core Hospital of Kochi, Japan [PDF]
, 2015 Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2007, invasive pneumococcal disease has declined, but the incidence of Streptococcus pneumoniae serotype 19A has risen worldwide.
Akane Kanazawa +10 more
core +1 more source